Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group. Issue 1 (24th October 2013)

• Record Type: Journal Article
• Authors: Tafreshi, Ali; Thientosapol, Eddy; Liew, Mun Sem; Guo, Yuan; Quaggiotto, Melissa; Boyer, Michael; Davis, Ian D
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 10:Issue 1(2014:Mar.)
• Page Start: 60
• Page End: 65
• Publication Date: 2013-10-24
• Subjects: Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.12122
• Languages: English
• ISSNs: 1743-7555

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="ajco12122-sec-0001" sec-type="section"> <title>Aim</title> <p>To assess the response rate and safety of sorafenib in different subpopulations of patients with advanced renal cell carcinoma (RCC).</p> </sec> <sec id="ajco12122-sec-0002" sec-type="section"> <title>Methods</title> <p>Single‐arm open access trial. Key eligibility: advanced RCC with either clear‐cell or non‐clear‐cell histopathology; progression on prior systemic chemotherapy or treatment naïve. Sorafenib was commenced at 400 mg twice daily continuously.</p> </sec> <sec id="ajco12122-sec-0003" sec-type="section"> <title>Results</title> <p>A total 47 participants with metastatic RCC were treated with sorafenib. Overall, 1 participant experienced complete response, 6 (13%) had documented partial response (PR) and 29 (62%) had stable disease (SD) as the best response. Eight (17%) had non‐clear‐cell histopathology and five (10%) had sarcomatoid features. In the non‐clear‐cell histopathology cohort, five participants (62.5%) had SD. Twenty‐three (49%) participants were treatment naïve; of these, 1/23 showed CR, 5/23 experienced PR and 13/23 had SD (clinical benefit: 83%). Overall, 14 (30%) and 22 (47%) participants had high‐risk status according to MSKCC (Memorial Sloan‐Kettering Cancer Center) and Heng prognostic scores, respectively. In the MSKCC poor prognostic group (14 participants), one participant had CR, two participants showed PR and eight participants had SD (clinical benefit: 79%). In Heng poor prognostic group (22 participants), 1 participant experienced CR, 2 participants showed PR and 13 had SD (clinical benefit: 73%). Hand–foot syndrome (53%), rash (47%), fatigue (42%), nausea (40%), anorexia (34%) and diarrhea (32%) were the most common adverse events.</p> </sec> <sec id="ajco12122-sec-0004" sec-type="section"> <title>Conclusions</title> <p>This study confirms the efficacy and tolerability of sorafenib in a different spectrum of advanced RCC patients including non‐clear‐cell histology, poor prognostic status and as first‐line treatment.</p> </sec> </abstract>